In October 2020, India and South Africa filed a request at the World Trade Organization (WTO) to create an exemption from an international treaty known as TRIPS (Trade-Related aspects of Intellectual Property Rights) for technologies, drugs, and vaccines used to respond to the COVID-19 pandemic. If the WTO adopts the waiver, countries could refuse to issue and protect IP rights for those technologies.
Some argue that the waiver is a necessary measure that would give a boost to the global fight against COVID-19, but others contend it would do little to help defeat the current pandemic and could hinder future innovation. An expert panel joined us to discuss the proposed waiver and weigh the arguments on each side of the debate.
In October, members of RTP's Intellectual Property Working Group published a white paper on the same topic, which you can read here.
- Andrei Iancu, Partner, Irell & Manella LLP
- David Kappos, Partner, Cravath Swaine & Moore LLP
- Arti Rai, Elvin R. Latty Professor of Law, Duke University School of Law
- [Moderator] Saurabh Vishnubhakat, Professor of Law, Texas A&M University School of Law
Visit our website – www.RegProject.org – to learn more, view all of our content, and connect with us on social media.
As always, the Federalist Society takes no position on particular legal or public policy issues; all expressions of opinion are those of the speaker.